Search results
Showing 31 to 45 of 67 results for hepatocellular carcinoma
This guideline covers assessing and managing suspected or confirmed cirrhosis in people who are 16 years or older. It aims to improve how cirrhosis is identified and diagnosed, and gives advice on the monitoring, prevention and early management of complications.
Metastatic malignant disease of unknown primary origin in adults: diagnosis and management (CG104)
This guideline covers diagnosing and managing secondary cancer in people aged 18 and over when the site of the primary cancer is unknown. This includes people who have had treatment for cancer before. It aims to improve quality of life by offering advice on tests for identifying the site of the primary cancer and options for managing the person’s condition.
Tenofovir disoproxil for the treatment of chronic hepatitis B (TA173)
Evidence-based recommendations on tenofovir disoproxil for treating chronic hepatitis B.
Elafibranor for previously treated primary biliary cholangitis (TA1016)
Evidence-based recommendations on elafibranor (Iqirvo) for previously treated primary biliary cholangitis in adults.
Ex-vivo hepatic resection and reimplantation for liver cancer (IPG298)
Evidence-based recommendations on ex-vivo hepatic resection and reimplantation for liver cancer. This involves removing the liver from the body, cutting away the diseased tissue, and reimplanting the remaining tumour-free liver into the patient.
View recommendations for IPG298Show all sections
Sections for IPG298
Image-guided percutaneous laser ablation for primary and secondary liver tumours (IPG788)
Evidence-based recommendations on image-guided percutaneous laser ablation for primary and secondary liver tumours. This involves heating up liver tissue to destroy tumours.
View recommendations for IPG788Show all sections
Nivolumab for untreated advanced hepatocellular carcinoma [ID1248]
Discontinued Reference number: GID-TA10221
Pembrolizumab for previously treated advanced hepatocellular carcinoma [ID1458]
Discontinued Reference number: GID-TA10380
Evidence-based recommendations on sofosbuvir (Sovaldi) for treating some types of chronic hepatitis C (HCV)
View recommendations for TA330Show all sections
Cabozantinib with atezolizumab for untreated advanced hepatocellular carcinoma [ID3940]
Discontinued Reference number: GID-TA10830
Awaiting development Reference number: GID-TA11653 Expected publication date: TBC
Discontinued Reference number: GID-TA10811
Awaiting development Reference number: GID-TA11538 Expected publication date: TBC
ADI-PEG 20 for previously treated hepatocellular carcinoma [ID1025]
Discontinued Reference number: GID-TA10259
Durvalumab for untreated unresectable hepatocellular carcinoma [ID4068]
Discontinued Reference number: GID-TA11041